Cargando…

The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome

OBJECTIVE: Based on a retrospective cohort study, to investigate the value of rivaroxaban combined with ticagrelor in antithrombotic therapy after PCI in patients with nonvalvular atrial fibrillation with acute coronary syndrome. METHODS: A total of 60 patients from January 2019 to May 2021 accepted...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhengwang, Qiu, Xiaotang, Yang, Hua, Wu, Xiaocui, Ye, Wenjing, Zheng, Xinbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649311/
https://www.ncbi.nlm.nih.gov/pubmed/36387358
http://dx.doi.org/10.1155/2022/4807175
_version_ 1784827768762007552
author Liu, Zhengwang
Qiu, Xiaotang
Yang, Hua
Wu, Xiaocui
Ye, Wenjing
Zheng, Xinbing
author_facet Liu, Zhengwang
Qiu, Xiaotang
Yang, Hua
Wu, Xiaocui
Ye, Wenjing
Zheng, Xinbing
author_sort Liu, Zhengwang
collection PubMed
description OBJECTIVE: Based on a retrospective cohort study, to investigate the value of rivaroxaban combined with ticagrelor in antithrombotic therapy after PCI in patients with nonvalvular atrial fibrillation with acute coronary syndrome. METHODS: A total of 60 patients from January 2019 to May 2021 accepted therapy with antithrombotic therapy after PCI. The patients treated with ticagrelor were set as the control group, and those given rivaroxaban combined with ticagrelor were set as the research group. The curative effect, myocardial level, TIMI blood flow grade, platelet aggregation rate, and the incidence of cardiovascular events were taken from the comparisons. RESULTS: The research group's therapeutic impact was superior to the control group's therapeutic impact, and the value was higher. After treatment, the myocardial levels of the two groups decreased, and the levels of troponin I, creatine kinase isoenzyme, and hypersensitive C-reactive protein in the research group were greatly less than those in the control group, and the difference was statistically significant (P < 0.05). After operation, the TIMI blood flow classification in the experimental group was better than that in the control group, and the difference was statistically significant (P < 0.05). The experimental group's platelet aggregation incidence was considerably lower than the control group's platelet aggregation incidence at 0.5 and 2 hours following surgery, and the difference was statistically significant (P < 0.05). The incidence of acute myocardial infarction, cardiogenic death, and intractable angina pectoris in the research group was significantly lower than that in the control group. CONCLUSION: Rivaroxaban combined with ticagrelor in the treatment of nonvalvular atrial fibrillation with acute coronary syndrome after percutaneous coronary intervention; the TIMI blood flow grade is better than ticagrelor, which is of great significance to reduce mortality and has high safety in clinical application.
format Online
Article
Text
id pubmed-9649311
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-96493112022-11-15 The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome Liu, Zhengwang Qiu, Xiaotang Yang, Hua Wu, Xiaocui Ye, Wenjing Zheng, Xinbing Evid Based Complement Alternat Med Research Article OBJECTIVE: Based on a retrospective cohort study, to investigate the value of rivaroxaban combined with ticagrelor in antithrombotic therapy after PCI in patients with nonvalvular atrial fibrillation with acute coronary syndrome. METHODS: A total of 60 patients from January 2019 to May 2021 accepted therapy with antithrombotic therapy after PCI. The patients treated with ticagrelor were set as the control group, and those given rivaroxaban combined with ticagrelor were set as the research group. The curative effect, myocardial level, TIMI blood flow grade, platelet aggregation rate, and the incidence of cardiovascular events were taken from the comparisons. RESULTS: The research group's therapeutic impact was superior to the control group's therapeutic impact, and the value was higher. After treatment, the myocardial levels of the two groups decreased, and the levels of troponin I, creatine kinase isoenzyme, and hypersensitive C-reactive protein in the research group were greatly less than those in the control group, and the difference was statistically significant (P < 0.05). After operation, the TIMI blood flow classification in the experimental group was better than that in the control group, and the difference was statistically significant (P < 0.05). The experimental group's platelet aggregation incidence was considerably lower than the control group's platelet aggregation incidence at 0.5 and 2 hours following surgery, and the difference was statistically significant (P < 0.05). The incidence of acute myocardial infarction, cardiogenic death, and intractable angina pectoris in the research group was significantly lower than that in the control group. CONCLUSION: Rivaroxaban combined with ticagrelor in the treatment of nonvalvular atrial fibrillation with acute coronary syndrome after percutaneous coronary intervention; the TIMI blood flow grade is better than ticagrelor, which is of great significance to reduce mortality and has high safety in clinical application. Hindawi 2022-11-03 /pmc/articles/PMC9649311/ /pubmed/36387358 http://dx.doi.org/10.1155/2022/4807175 Text en Copyright © 2022 Zhengwang Liu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liu, Zhengwang
Qiu, Xiaotang
Yang, Hua
Wu, Xiaocui
Ye, Wenjing
Zheng, Xinbing
The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
title The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
title_full The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
title_fullStr The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
title_full_unstemmed The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
title_short The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
title_sort value of rivaroxaban combined with ticagrelor in antithrombotic therapy after pci in patients with nonvalvular atrial fibrillation with acute coronary syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649311/
https://www.ncbi.nlm.nih.gov/pubmed/36387358
http://dx.doi.org/10.1155/2022/4807175
work_keys_str_mv AT liuzhengwang thevalueofrivaroxabancombinedwithticagrelorinantithrombotictherapyafterpciinpatientswithnonvalvularatrialfibrillationwithacutecoronarysyndrome
AT qiuxiaotang thevalueofrivaroxabancombinedwithticagrelorinantithrombotictherapyafterpciinpatientswithnonvalvularatrialfibrillationwithacutecoronarysyndrome
AT yanghua thevalueofrivaroxabancombinedwithticagrelorinantithrombotictherapyafterpciinpatientswithnonvalvularatrialfibrillationwithacutecoronarysyndrome
AT wuxiaocui thevalueofrivaroxabancombinedwithticagrelorinantithrombotictherapyafterpciinpatientswithnonvalvularatrialfibrillationwithacutecoronarysyndrome
AT yewenjing thevalueofrivaroxabancombinedwithticagrelorinantithrombotictherapyafterpciinpatientswithnonvalvularatrialfibrillationwithacutecoronarysyndrome
AT zhengxinbing thevalueofrivaroxabancombinedwithticagrelorinantithrombotictherapyafterpciinpatientswithnonvalvularatrialfibrillationwithacutecoronarysyndrome
AT liuzhengwang valueofrivaroxabancombinedwithticagrelorinantithrombotictherapyafterpciinpatientswithnonvalvularatrialfibrillationwithacutecoronarysyndrome
AT qiuxiaotang valueofrivaroxabancombinedwithticagrelorinantithrombotictherapyafterpciinpatientswithnonvalvularatrialfibrillationwithacutecoronarysyndrome
AT yanghua valueofrivaroxabancombinedwithticagrelorinantithrombotictherapyafterpciinpatientswithnonvalvularatrialfibrillationwithacutecoronarysyndrome
AT wuxiaocui valueofrivaroxabancombinedwithticagrelorinantithrombotictherapyafterpciinpatientswithnonvalvularatrialfibrillationwithacutecoronarysyndrome
AT yewenjing valueofrivaroxabancombinedwithticagrelorinantithrombotictherapyafterpciinpatientswithnonvalvularatrialfibrillationwithacutecoronarysyndrome
AT zhengxinbing valueofrivaroxabancombinedwithticagrelorinantithrombotictherapyafterpciinpatientswithnonvalvularatrialfibrillationwithacutecoronarysyndrome